ArticleScientific reports2025
Theranostic application of radiolabeled HER2-targeting single-domain antibodies (RAD202) in preclinical setting.
Betül Altunay et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it